Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells

被引:220
作者
Wielinga, PR
van der Heijden, I
Reid, G
Beijnen, JH
Wijnholds, J
Borst, P
机构
[1] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands
[3] Slotervaart Hosp, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands
[4] Royal Dutch Acad Sci, Netherlands Ophthalm Res Inst, NL-1105 BA Amsterdam, Netherlands
关键词
D O I
10.1074/jbc.M212723200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cyclic nucleotides are known to be effluxed from cultured cells or isolated tissues. Two recently described members of the multidrug resistance protein family, MRP4 and MRP5, might be involved in this process, because they transport the 3',5'-cyclic nucleotides, cAMP and cGMP, into inside-out membrane vesicles. We have investigated cGMP and cAMP efflux from intact HEK293 cells overexpressing MRP4 or MRP5. The intracellular production of cGMP and cAMP was stimulated with the nitric oxide releasing compound sodium nitroprusside and the adenylate cyclase stimulator forskolin, respectively. MRP4- and MRP5-overexpressing cells effluxed more cGMP and cAMP than parental cells in an ATP-dependent manner. In contrast to a previous report we found no glutathione requirement for cyclic nucleotide transport. Transport increased proportionally with intracellular cyclic nucleotide concentrations over a calculated range of 20-600 muM, indicating low affinity transport. In addition to several classic inhibitors of organic anion transport, prostaglandins A(1) and E-1, the steroid progesterone and the anti-cancer drug estramustine all inhibited cyclic nucleotide efflux. The efflux mediated by MRP4 and MRP5 did not lead to a proportional decrease in the intracellular cGMP or cAMP levels but reduced cGMP by maximally 2-fold over the first hour. This was also the case when phosphodiesterase-mediated cyclic nucleotide hydrolysis was inhibited by 3-isobutyl-1-methylxanthine, conditions in which efflux was maximal. These data indicate that MRP4 and MRP5 are low affinity cyclic nucleotide transporters that may at best function as overflow pumps, decreasing steep increases in cGMP levels under conditions where cGMP synthesis is strongly induced and phosphodiesterase activity is limiting.
引用
收藏
页码:17664 / 17671
页数:8
相关论文
共 52 条
  • [31] Urinary levels of cyclic guanosine monophosphate (cGMP) in patients with cancer of the uterine cervix: a valuable prognostic factor of clinical outcome?
    Orbo, A
    Jaeger, R
    Sager, G
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (09) : 1460 - 1462
  • [32] PATEL MJ, 1995, J PHARMACOL EXP THER, V273, P16
  • [33] Interleukin-1β stimulates cyclic GMP efflux in brain astrocytes
    Pedraza, CE
    Baltrons, MA
    García, A
    [J]. FEBS LETTERS, 2001, 507 (03) : 303 - 306
  • [34] Poulopoulou C, 1998, J PHARMACOL EXP THER, V286, P99
  • [35] Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5
    Reid, G
    Wielinga, P
    Zelcer, N
    De Haas, M
    Van Deemter, L
    Wijnholds, J
    Balzarini, J
    Borst, P
    [J]. MOLECULAR PHARMACOLOGY, 2003, 63 (05) : 1094 - 1103
  • [36] RINDLER MJ, 1978, J BIOL CHEM, V253, P5431
  • [37] MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs
    Schuetz, JD
    Connelly, MC
    Sun, DX
    Paibir, SG
    Flynn, PM
    Srinivas, RV
    Kumar, A
    Fridland, A
    [J]. NATURE MEDICINE, 1999, 5 (09) : 1048 - 1051
  • [38] Molecular mechanisms of prostaglandin transport
    Schuster, VL
    [J]. ANNUAL REVIEW OF PHYSIOLOGY, 1998, 60 : 221 - 242
  • [39] Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions
    Soderling, SH
    Beavo, JA
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2000, 12 (02) : 174 - 179
  • [40] Effect of efflux of guanosine 3',5' cyclic monophosphate (cGMP) on the regulation of intracellular levels of cGMP in the inner medullary collecting duct
    Stoos, BA
    Garvin, JL
    [J]. BIOCHEMICAL PHARMACOLOGY, 1997, 53 (05) : 631 - 636